Oncology Precision Medicine Market

Market Overview

The global oncology precision medicine market size was valued at USD 67.2 billion in 2024 and is projected to grow from USD154.59 billion in 2025 to reach USD 170.04 billion in 2033, growing at a CAGR of 11.1% during the forecast period (2025–2033)

Oncology precision medicine is the delivery of customized medical therapies, which are customized to the genetic make-up, tumor profile and lifestyle of that specific cancer patient. Ultimately, oncology precision medicine is a great shift from using genomic sequencing, biomakers, and other complex diagnostics to allow clinician decision making with targeted therapies individualized to the unique patient profile, rather than providing one treatment option for all cancers. Currently, oncology precision medicine is implemented in several cancer types including breast, lung, colorectal, prostate, and hematological cancers. Oncology precision medicine is an integrated process involving the diagnosis and therapy. With advanced technologies including next-generation sequencing, pharmacogenomics, and companion diagnostics, it is possible to identify actionable mutations, which allow patients to receive individualized therapies that specifically target the cancer-driving genes or pathways. Targeting these pathways in patients provides more effective therapies, with less and better-tolerated side effects, with improved clinical outcomes.

Market Dynamics

Market Drivers

Increasing incidence of cancer and rise in demand for personalized therapies

The growing cancer burden around the globe is a major factor contributing to the increasing need for oncology precision medicine. According to the World Health Organization (WHO), cancer takes a toll on the global population as a leading cause of death, accounting for 10 million deaths in 2020. With the rise of cancer cases, especially in maturing patient demographics, healthcare systems are moving away from the one-size-fits-all approach to a more individually tailored treatment for higher efficacy and patient safety. Precision oncology has paved the way in determining targeted therapies by way of establishing genetic mutations, identifying biomarkers, and taking a profile of individual tumors through next-generation sequencing (NGS). A good example would be patients with non-small-cell lung cancer (NSCLC) who present with epidermal growth factor receptor (EGFR) mutations are able to make effective use of targeted therapies such as osimertinib, not only providing a safer and more efficacious therapy alternative to conventional chemotherapy but modifying patient outcomes for the better. This method of personalized medicine not only marks a win in survival rates, but also has an influence in improving quality of life. With governments and social health organizations putting these types of genomic programs first, including the U.S. National Cancer Institute’s Precision Medicine Initiative, the need for personalized care in cancer is expected to be where innovation, commercialization and investment grow in oncology precision medicine solutions.

Technological Improvements in Genomic Sequencing and Molecular Diagnostic Testing

The rapid advancement of genomic sequencing and molecular diagnostic testing has led to remarkable growth in precision medicine across the field of oncology. Technologies like next-generation sequencing (NGS), digital PCR, and multiplex biomarker assays allow us to quickly, accurately, and affordably characterize the genetic make-up of tumors. This has expanded our ability to identify actionable mutations to help guide clinicians in selecting targeted therapies for their patients. For example, Foundation Medicine developed a comprehensive genomic profiling test—Foundation One CDx—that analyzes more than 300 genes associated with cancer. As a companion diagnostic, the FDA has approved (and Foundation One is reimbursed by insurance) Foundation One to detect mutations associated with multiple therapies, such as those directed against BRCA mutations for patients with breast and ovarian cancer. These advancements allow oncologists and other clinicians to select treatments for their patients based on the presence of specific molecular alterations rather than solely on tumor location.

Improvements in sequencing technology have made it increasingly affordable and now quicker than ever, and increased access to genomic profiling is seen at the patient or clinical level. Molecular profiling is now often incorporated into clinical practice in hospitals and diagnostic labs as a routine part of the oncology workup. This allows clinicians to make decisions on diagnosis and treatment, and actively monitor tumors faster than ever, especially for more complex or late-stage cancers. As access to diagnostic platforms becomes more widely available across the globe, we expect that the wider adoption of genomic profiling and molecular diagnostics will continue to fuel the market’s growth.

Market Restraints

High Cost and Limited Accessibility of Precision Oncology Solutions

A key limitation to the growth of the oncology precision medicine market is the high cost associated with genomic testing, targeted therapies and infrastructure to deliver. Precision oncology brings clinical decision support systems such as next-generation sequencing (NGS), companion diagnostics, and bioinformatics platforms. Each genomic test could cost thousands of dollars per patient (e.g., PARP inhibitors or checkpoint inhibitors targeting therapy) and are often considerably more expensive than conventional chemotherapy. The cost of comprehensive genomic profiling testing such as of Foundation One CDx can be above ~5,000 USD per analysis and many therapies such as pembrolizumab (Keytruda) can exceed ~150,000 USD annually, pricing out many patients especially those located in middle- and low-income countries. Furthermore, inadequate disease and genomic characterization such as limited coverage for genomic profiling and limited reimbursement for personalized therapies by insurance companies becomes barriers to adoption and limits equitable access to patient’s care pathways. In many areas, genomic tests and personalized therapies (testing and therapies) become out-of-pocket expenses if not adequately covered by the government-funded or private insurance systems or with many tests and therapies uncovered at all. Financial barriers to access and adoption results in health-care inequities. Until such barriers to reimbursement or broader coverage policies or policy measures to decrease the cost of testing and therapies are implemented, the oncology precision medicine market is likely to encounter resistance, especially in resource-limited planning regions or in emerging economies.

Segmental Analysis

By Cancer Type

Breast Cancer accounted for the largest market share in 2024, driven by a high incidence rate and general population awareness stemming from common screening and early detection initiatives. Genetic tests, like BRCA1/2 and HER2 status assessments, allow for tailored treatment programs. Therapies like trastuzumab and ribociclib have shaped the foundation of therapies for patients with HER2-positive and HR-positive cancers, establishing a demand from physicians for precision medicine. Lung Cancer is expected to develop well in the future, with a high demand for molecular profiling of mutations (EGFR, ALK, and ROS1). Specific targeted drugs, such as osimertinib and alectinib for non-small cell lung cancer (NSCLC), demonstrate the potential positive effect of precision medicine on survival. Colorectal Cancer clinical practice is strong, driven by the increasing use of KRAS, NRAS, and MSI testing, which is accompanied by increasing real-world integration of precision-based treatment and immunotherapy with targeted agents in improving outcomes of patients with advanced colorectal cancer. More recently, Prostate Cancer appears to be increasing its uptake of precision tools, especially for metastatic cases, where clinical genetic testing identifies patients for therapies using PARP inhibitors.

By Technology

Genomics dominated the market in 2024, with the largest share due to the importance of gene sequencing in identifying tumor mutations. Whole genome and whole exome sequencing are being applied to create individualized treatment plans in almost every cancer. Pharmacogenomics continues a steady increase in use, as healthcare providers are interested in the effects of inherited genetic variations on drug metabolism and effectiveness. This technology as a precision therapeutic is a way to limit adverse effects and tailor drug therapy dosages, especially in therapies using cytotoxic agents and tyrosine kinase inhibitors. Companion Diagnostics is a key component for delivering precision oncology, allowing clinicians to have molecular insight into which patients are most likely to respond to a targeted therapeutic. Companion Diagnostics are most often co-developed with targeted drugs, rough examples are EGFR tests with erlotinib and KRAS tests with cetuximab. Molecular Diagnostics continues to have a greater impact on decisions that a healthcare provider uses during patient management, mainly in hospital laboratories and diagnostic laboratories. There is no shortage of available molecular diagnostic technologies – qPCR, FISH, NGS panels – on the market today, often for the same target, but the advantage is decreased cost and resources needed to identify gene fusions, gene amplifications, and gene mutations. Bioinformatics is also becoming far more widespread since it gives an opportunity to turn complex genomic data into clinical insight. As sequencing produces greater volumes of data, bioinformatics tools allow the identification of druggable targets, can track resistance mutations and assist in clinical decision-making.

By Application

Targeted Therapy was the leading application segment in 2024, due to extensive availability of approved targeted drugs in the market, and clinical evidence demonstrating success of mutation specific therapies. Agents working more recently based on the specific alteration, such as trastuzumab targeting HER-2, vemurafenib targeting BRAF V600E, and larotrectinib targeting NTRK, have all resulted in greater than 40% response rates. Immunotherapy is quickly becoming the next largest application and is growing especially rapidly with the use of checkpoint inhibitors, namely pembrolizumab and nivolumab. Precision Diagnostics in the drug development space can be guided from a number of relevant factors including PD-L1 expression, microsatellite instability (MSI) and tumor mutational burden (TMB) testing to better determine patients who would benefit from treatment, while minimizing treatment to nonresponsive patients. Prognostics and Predictive diagnostics applications are increasingly considering the use of information that can help determine risk of disease, and predict patient response to therapy. As an example, genomic classifiers such as Oncotype DX, and molecular signatures are now used routinely to determine the risk and intensity of treatment in breast cancer. Personalized Screening is a strong potential application area, particularly for those patients with hereditary risk factors for cancer, using liquid biopsies and germline mutation panels to improve early detection and intervention in high risk patient populations thus improving their prognosis for long term survival.

By End-User

In 2024, Hospitals and Clinics accounted for the majority of the oncology precision medicine market, as they play the crucial role of diagnosing and treating cancer. Large cancer treatment centers, as well as specialty clinics, routinely incorporate genomic testing and targeted therapies as an integral part of their comprehensive care programs and, thus, this space is attracting much interest and growing more rapidly. Pharmaceutical and Biotechnology Companies are helping drive market growth. Diagnostic Laboratories serve as the ‘glue’ in the onco-precision medicine process, providing a unique, professional service with the preparation of NGS panels, companion diagnostics, molecular profiling, and other services. The growing demand for reliable and reproducible high throughput, high accuracy testing has resulted in a steady increase in this segment. Academic and Research Institutions are also coin contributors to the space through discovery of novel biomarkers, to clinical validation of those novel tests, and to develop early stage therapeutic options. Academic institutions often partner with Biotech companies and hospitals to facilitate innovation and commercial development.

Regional Analysis

North America

In 2024, North America is expected to lead the oncology precision medicine market, with its market share at 44.0%, valued at around USD 34.2 billion. This will be attributed to significant funding directed towards oncology research, advanced genomic testing platforms readily available, and widespread uptake of targeted therapies. For example, the use of government-led programmes such as the Cancer Moonshot, the developed regulatory system for fast tracked application for precision oncology drugs, and coverage for personalized therapies through insurance in the U.S. are all examples of combined efforts that strongly influence market size in North America. For example, innovation in AI and molecular sciences, including next-generation sequencing (NGS) based screening and clinical diagnostics, should continue to spur the growth of oncology precision medicine in this region through 2033.

Europe

With about a quarter of the market in 2024, Europe has the second largest market share globally, valued at about USD xx billion in 2024. The initiatives Genomics England, the 1+ Million Genomes initiative and France Médecine Génomique 2025 are essentially promoting harmonization of genomics as a routine part of cancer care. Leading nations like France, Germany, the UK, and France are increasing precision diagnostics, as well as partnering with biopharma companies to co-develop companion diagnostics. The EMA is also collaborating on personalized therapies and committed to spending limited resources on translational oncology research that can expedite the maturity of genomics in the health care system. Differences in reimbursement in different countries, however, could constrain broad-based adoption.

Asia-Pacific

Asia-Pacific is the fastest expanding region, accounting for a market share of xx% in 2024, with the market size projected at USD 18.2 billion in 2033. Several factors are driving the growth in this region, including an increase in cancer incidence, access to more advanced diagnostics (e.g., high-throughput sequencing), and precision medicine programs at the national level. For example, China’s “Healthy China 2030” plan, and Japan’s approval system for companion diagnostics, are enhancing primacy for innovation and market reach. Indian, South Korean, and Australian genomic platforms will be enhanced by increasing government and private investments. The region also benefits from having a rapidly growing middle-class population with increasing health awareness, further propelled by technology-driven healthcare startups. With these factors, it will continue to be an important growth region up to 2033.

Recent Development

1. January 2025: GSK announced it is acquiring IDRx, a U.S.-based cancer drug developer, for as much as $1.15 billion. The acquisition will broaden GSK’s oncology pipeline with a focus on gastrointestinal stromal tumors via IDRx’s flagship candidate IDRX-42 which targets KIT gene mutations.
2. December 2024: Eli Lilly completed the acquisition of POINT Biopharma, a radiopharmaceutical company focused on developing radioligand therapies for cancer treatment. This transaction represented Lilly’s entry into the radioligand therapy space, increasing its oncology treatment portfolio.